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F. Kabir et al.482Results: HOMA%B was significantly lower in IFG (p ¼
0.0001) and IFG-IGT (p ¼ 0.001) subjects. HOMA%S in
IGT (p ¼ 0.0001) and IFG-IGT (p ¼ 0.001) subjects were
significantly lower compared to controls. The fasting
serum visfatin (ng/ml) level was significantly higher in
IFG (5.08  2.16, p ¼ 0.0001), IGT (4.75  2.81, p ¼
0.0001) and IFG-IGT subjects (4.33  2.68, p ¼ 0.013)
compared to controls (2.60  1.2). In binary logistic
regression analysis, visfatin has found significantly asso-
ciated with IFG (B ¼ 0.198, p ¼ 0.040), IGT (B ¼ 0.162,
p ¼ 0.043) and IFG-IGT (B ¼ 0.188, p ¼ 0.044). Visfatin
was also found significantly correlated with postprandial
serum glucose and blood pressure in IGT subjects. Fre-
quency of IFG, IGT and IFG-IGT subjects increased
with increasing visfatin concentrations.
Conclusions: Serum visfatin appear to be associated with
IFG, IGT and IFG-IGT. Postprandial serum glucose and
blood pressure are positively associated with visfatin
levels in IGT subjects.
Keywords: Hyperglycaemia; Insulin resistance; Prediabetes;
Visfatin
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Visfatin is an adipocytokine that was identified in 2005.1
This cytokine was named based on it being primarily
produced by visceral fat. Visfatin has a molecular weight of
52 kda and is composed of 491 amino acid residues.
Visfatin is identical to pre-Beta-cell colony-enhancing fac-
tor (PBEF), described in 1994 as a cytokine produced by
lymphocytes, acting on lymphocyte maturation and inflam-
matory regulation.2 In addition to being produced in human
leukocytes and adipose tissue, visfatin is also expressed in
human and animal hepatocytes and muscles3,4 and in
animal adipocytes, kidney and heart.5e7 Visfatin is believed
to exhibit endocrine, paracrine and autocrine activities.
The autocrine effects of visfatin may play an important
role in regulating insulin sensitivity in the liver.6
In mice, visfatin was found to play an important role in the
reduction of the blood glucose concentration.1 Visfatin
displays insulin mimetic effects, which was thought to
be mediated through the phosphorylation of signal
transduction proteins in the insulin signalling pathway and
through binding to the insulin receptor at a site distinct from
that of insulin.8 Recent studies also demonstrated that serum
visfatin levels were significantly higher in the diabetic
compared with the nondiabetic group and found a significant
positive correlation of serum visfatin levels with the obesity
indicator BMI and waist circumference, even after adjusting
for age, sex, smoking status, bloodpressure and lipidprofile.9,10
Visfatin is an essential enzyme in NAD (nicotinamide
adenine di-nucleotide) production, and it exists both in intraand extracellular environments.7 Mice with heterozygous
mutations in the visfatin gene display glucose intolerance
mainly due to insulin secretion deficiency, and this insulin
secretion defect can be corrected by the administration of
nicotinamide mononucleotide (NMN), the product of
visfatin in NAD biosynthesis.7 Because the pancreas has
very low levels of intracellular visfatin, some have
suggested that the maintenance of high NMN circulating
levels by extracellular visfatin are critical for normal beta-
cell function.7 A study that investigated glucose uptake in
animal hepatocytes with reduced visfatin expression
demonstrated reduced NAD biosynthesis and a
significantly decreased incremental uptake of glucose after
stimulation with insulin when compared with control
hepatocytes with normal visfatin expression.6 A negative
correlation of visfatin levels with beta-cell function was
demonstrated by studying acute insulin secretion assessed via
an intravenous glucose tolerance test.11 Furthermore,
continuous glucose infusion in humans acutely increases
visfatin levels. This effect is suppressed by insulin or
somatostatin infusion.12 The relationship between insulin
resistance and blood or tissue visfatin concentrations
remains unclear. Some studies indicate that blood visfatin
concentrations significantly correlate with insulin resistance
or type 2 diabetes but not with body fat percentage or
body mass index (BMI).13,14 Other studies demonstrated
that the association between diabetes and blood visfatin
concentrations was not significant after adjusting for body
mass index (BMI) and waist circumference.15 A recent
study found that visfatin levels were inversely associated
with insulin resistance in non-diabetic obese women with
energy restricted diet intervention.16
The natural history of type 2 diabetes (T2D) has been
demonstrated to pass through an intermediate stage of
impaired fasting glucose (IFG) and/or impaired glucose
tolerance (IGT), which is designated as impaired glucose
regulation (IGR) by the World Health Organization
(WHO) or pre-diabetes by the American Diabetic Associa-
tion (ADA). The association of visfatin has not been
extensively studied with the three groups of prediabetic
(IFG, IGT and IFG-IGT) subjects, yet it is important to
know whether visfatin levels increase before the onset of
diabetes.Materials and Methods
Seventy-five prediabetic subjects (IFG 17; IGT 44 and
IFG-IGT 14) were recruited in this study from the Out-
Patient Department (OPD) of BIRDEM (Bangladesh Insti-
tute of Research and Rehabilitation in Diabetes, Endocrine
and Metabolic Disorders) Hospital, Dhaka. The subjects
were considered as IFG, IGT or IFG-IGT based on the
WHO guidelines.17 Fifty-one healthy subjects without a
family history of diabetes were also recruited in this study to
serve as the controls.
On a prescheduled morning, the subjects were requested
to arrive after overnight fast (8e10 h to provide a fasting
blood sample. The theme of the study was explained to the
subjects and a written consent was taken. After taking 10 ml
of fasting blood samples, the subjects were given 75 g of
glucose dissolved in 250 ml of water. The blood was taken via
Visfatin is associated with post-challenged plasma glucose levels in IGT subjects. 483venepuncture during the 2 h after the glucose load. After 10e
15 min of collection, the blood samples were centrifuged for
10e15 min at 3000 rpm to obtain the serum, which was then
kept frozen at 30 C until further biochemical analysis.
The anthropometric indices and total body fat mass were
determined following standard procedures. Glucose was
measured using the glucose-oxidase method, and the lipid
profiles were measured using the enzymatic endpoint method
(Randox Laboratories, Northern Ireland, UK). Insulin
(Linco Research, Missouri 63304, USA) and plasma visfatin
(ALPCO Diagnostics, USA, cs@alpco.com) were measured
using an enzyme linked immunosorbent assay (ELISA).
Visfatin intra assay variation was measured using 6 replicates
of a pooled serum sample, and the coefficient of variation
was 8%. Insulin secretory capacity (HOMA%B) and insulin
sensitivity (HOMA%S) were determined using fasting
glucose and fasting insulin using HOMA-Sigma software.18Statistical analysis
The data were analysed using Statistical Package for So-
cial Science (SPSS, Chicago, Illinois, USA) for Windows
version 12. The quantitative variables were expressed as the
mean standard deviation (SD). The baseline characteristics
between the prediabetic groups (IFG, IGT and IFG-IGT)
and non-diabetic controls were assessed using student’s t-
test. The data that were not normally distributed were log
transformed before the analysis. The distribution of predia-
betes in the different quartiles of visfatin were analysed by
c2-test. The associations of the serum visfatin with
prediabetes were analysed using binary logistic regression.Table 1: Clinical characteristics and glycaemic, insulinaemic, lipidae
IFG-IGT subjects.
Controls, n ¼ 51 IFG, n ¼ 17 IGT, n ¼
M/F ratio 27/24 7/10 24/20
Age, yrs 42  6 45  7 42  7
BMI, kg/m2 24.5  4.1 24.3  3.3 25.3  4
WHR 0.91  0.06 0.94  0.06 0.93  0
BF (%) 28  6 31  7 30  7
SBP, mm-hg 110  13 113  9 116  1
DBP, mm-hg 74  8 78  6 76  1
FSG, mmol/l 5.1  0.4 6.4  0.3 5.3  0
PPSG, mmol/l 6.1  1.1 6.4  1.2 9.3  0
Insulin, mIU/ml 9.6  2.5 9.2  1.3 12.4  4
HOMA %B 107  25 68  14 121  4
HOMA %S 85  18 76  14 65  1
HOMA IR 1.17  0.21 1.38  0.24 1.69  0
TG, mg/dl 119  37 191  82 186  8
Chol, mg/dl 193  31 214  78 203  5
LDL, mg/dl 135  31 142  80 132  4
HDL, mg/dl 34  11 35  6 29  8
Visfatin (ng/ml) 2.6  1.2 5.08  2.16 4.75  2
Data are expressed as the mean  SD. IFG, impaired fasting glucose;
waist:hip ratio; WHtR, waist:height ratio; SBP, systolic blood pressure;
postprandial (2 h after 75 g glucose challenge) serum glucose; TG, trigly
B, insulin secretory capacity; HOMA-IR, Insulin resistance using the HThe correlations between the two continuous variables
were analysed using Spearman’s correlation. A p-value of
<0.05 was considered statistically significant.Results
The fasting insulin levels were significantly higher in the
IGT (p ¼ 0.002) and IFG-IGT (p ¼ 0.017) subjects
compared with the controls (Table 1). The mean TG levels
were significantly higher in the IFG (p ¼ 0.002), IGT
(p ¼ 0.0001) and IFG-IGT (p ¼ 0.013) subjects compared
with the controls. The insulin secretory capacity (HOMA%
B) was significantly lower in the IFG (p ¼ 0.0001) and IFG-
IGT (p ¼ 0.001) subjects and significantly higher in the IGT
subjects compared with the controls. Insulin sensitivity
(HOMA%S) was significantly lower in the IGT (p ¼ 0.0001)
and IFG-IGT (p ¼ 0.001) subjects compared with the con-
trols (Table 2). Insulin resistance (HOMA IR) was also
significantly higher in the IFG (p ¼ 0.031), IGT
(p ¼ 0.0001) and IFG-IGT (p ¼ 0.002) subjects compared
with the controls (Table 1).
The fasting serum visfatin (ng/ml) level was significantly
higher in the IFG (5.08  2.16, p ¼ 0.0001), IGT
(4.75  2.81, p ¼ 0.0001) and IFG-IGT (4.33  2.68,
p ¼ 0.013) subjects compared with the controls (2.60  1.20)
(Table 1). In the binary logistic regression analysis, when the
control group was set as the reference and the effects of age,
gender and BMI were justified, the serum visfatin levels
significantly associated with the IFG (B ¼ 0.198,
p ¼ 0.040), IGT (B ¼ 0.162, p ¼ 0.043) and IFG-IGT
(B ¼ 0.188, p ¼ 0.044) groups (Table 2).mic and serum visfatin status among the control, IFG, IGT and
44 IFG-IGT,
n ¼ 14
p-values
Control
vs. IFG
Control
vs. IGT
Control
vs. IFG-IGT
6/8 e e e
43  6 0.103 0.958 0.435
.6 26.3  5.5 0.881 0.366 0.167
.07 0.91  0.09 0.062 0.212 0.851
29  9 0.085 0.278 0.666
6 113  10 0.519 0.068 0.525
0 71  8 0.080 0.159 0.326
.5 6.4  0.3 0.0001 0.617 0.0001
.8 9.9  0.7 0.221 0.0001 0.0001
.7 11.8  3.0 0.538 0.002 0.017
5 79  18 0.0001 0.019 0.001
8 61  16 0.662 0.0001 0.001
.54 1.71  0.43 0.031 0.0001 0.002
9 197  101 0.002 0.0001 0.013
0 202  36 0.370 0.423 0.508
3 125  31 0.649 0.686 0.285
35  12 0.896 0.009 0.750
.81 4.33  2.68 0.0001 0.0001 0.013
IGT, impaired glucose tolerance; BMI, body mass index; WHR,
DBP, diastolic blood pressure; FSG, fasting serum glucose; PPSG,
ceride; Chol, cholesterol; HOMA%S, insulin sensitivity; HOMA%
OMA method; RBP4, retinol-binding protein-4.
Table 2: Binary logistic regression analysis of serum visfatin levels prediabetes with the control as the reference group adjusted for the
effects of covariate age, gender and BMI.
Variables Control vs, IFG Control vs. IGT Control vs. IFG-IGT
B S.E. p-value B S.E. p-value B S.E. p-value
Age 0.037 0.048 0.433 0.004 0.039 0.910 0.046 0.055 0.404
Gender 1.045 0.681 0.125 0.540 0.482 0.263 0.150 0.757 0.843
BMI 0.029 0.092 0.755 0.002 0.066 0.970 0.073 0.089 0.409
Visfatin 0.198 0.096 0.040 0.162 0.080 0.043 0.188 0.093 0.044
Constant 4.303 3.218 0.181 1.228 2.359 0.603 5.595 3.438 0.104
IFG, impaired fasting glucose; IGT, impaired glucose tolerance BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure.
F. Kabir et al.484In the Spearman correlation analysis, visfatinwas found to
be positively associated with both systolic (r¼ 0.33, p¼ 0.05)
and diastolic (r ¼ 0.41, p ¼ 0.017) blood pressure in the IGT
subjects. Postprandial (2 h after 75 g glucose ingestion) serum
glucose was also found to be positively correlated (r ¼ 0.36,
p ¼ 0.041) with the fasting serum visfatin levels in these
subjects. The insulin secretory capacity and insulin sensitivity
did not show a significant correlation with the fasting serum
visfatin levels (Table 3). The insulin secretory capacity
(HOMA B) was found to be significantly correlated with
the serum visfatin levels in the control subjects but not with
the other groups. Upon regression curve fitting, the fasting
serum visfatin level was significantly correlated with BMI in
the IFG (R2 ¼ 0.716, p ¼ 0.001) and IGT (R2 ¼ 0.180,
p ¼ 0.014) subjects and marginally significant in the IFG-
IGT (R2 ¼ 0.382, p ¼ 0.057) subjects, but it was not signifi-
cant in the controls (Figure 1).
To examine the association between the plasma visfatin
concentrations and other parameters related to insulin
resistance, we divided our study subjects into plasma visfatin
concentration quartiles (Table 4). The proportion of the
IFG, IGT and IFG-IGT subjects increased with increasing
visfatin concentrations, which is significantly associated in
the c2-test. Additionally, the female sex, body fat percentage,
diastolic blood pressure, post-challenge plasma glucose
levels, TG levels and HOMA-IR values positively correlated
with increasing visfatin concentrations. Body fat percentage,
diastolic blood pressure and postprandial plasma glucose in
the subjects of the fourth quartile were significantly higher
compared with the first quartile using unpaired student’s t
test. Similarly, the HOMA IR and TG values were also
shown significantly higher in the third quartile compared
with the first quartile.Table 3: Correlation of visfatin with blood pressure, glycaemic and i
Visfatin Vs Controls, n ¼ 51 IFG, n ¼ 17
SBP r ¼ 0.026, p ¼ 0.873 r ¼ 0.044, p ¼ 0
DBP r ¼ 0.108, p ¼ 0.508 r ¼ 0.159, p ¼ 0.5
PPSG r ¼ 0.15, p ¼ 0.46 r ¼ 0.35, p ¼ 0.26
Insulin r ¼ 0.32, p ¼ 0.12 r ¼ 0.57, p ¼ 0.
HOMA%B r ¼ 0.45, p ¼ 0.024 r ¼ 0.47, p ¼ 0.
HOMA%S r ¼ 0.29, p ¼ 0.15 r ¼ 0.34, p ¼ 0.40
HOMA IR r ¼ 0.22, p ¼ 0.39 r ¼ 0.377, p ¼ 0
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; SBP
postprandial (2 h after a 75 g glucose challenge) serum glucose; HOM
HOMA-IR, Insulin resistance using HOMA method.Discussion
This study, which examined the inflammatory mediator
visfatin in prediabetic subjects, has three major findings.
First, the fasting serum visfatin level was significantly higher
in the IFG, IGT and IFG-IGT subjects compared with the
controls, and binary logistic regression analysis showed a
significant association of visfatin with IFG, IGT and IFG-
IGT after adjusting for the effects of age, BMI and gender.
Second, the serum visfatin levels in the IGT subjects signifi-
cantly correlated with blood pressure and postprandial
blood glucose levels. Third, in the regression curve fitting, the
serum visfatin concentration was significantly and positively
associated with BMI in the IFG and IGT subjects.
Type 2 diabetes mellitus has been suggested to be a disease
of the innate immune system responsible for an ongoing
cytokine-mediated acute phase response and low-grade
chronic inflammation, which may be involved in the athero-
sclerosis exhibited in diabetes mellitus patients.19 Therefore,
it is important to determine whether signs of an activated
innate immune system are present before the onset of
type 2 diabetes mellitus. Recent studies documented that
the adipose tissue derived cytokine, visfatin, has a role in
the activation of insulin receptors in different cells.
Additionally, visfatin enhanced glucose and lipogenic
transfer in 3T3-L1 adipocytes and L6 myocytes and
decreased glucose secretion by hepatocytes in vitro.1 Visfatin
may be secreted from 3T3-L1 adipocytes and may be asso-
ciated with endoplasmic reticulum and Golgi or micro-vesi-
cles.20 Another study reported that hyperglycaemia might
increase the synthesis of visfatin in cultured adipocytes.12
This study attempted to measure the circulating visfatin
levels in healthy subjects of the Bangladeshi population. Thensulinaemic status among the study subjects.
IGT, n ¼ 44 IFG-IGT, n ¼ 14
.866 r ¼ 0.33, p ¼ 0.05 r ¼ 0.013, p ¼ 0.97
43 r ¼ 0.41, p ¼ 0.017 r ¼ 0.053, p ¼ 0.88
r ¼ 0.36, p ¼ 0.04 r ¼ 0.23, p ¼ 0.54
14 r ¼ 0.18, p ¼ 0.28 r ¼ 0.20, p ¼ 0.61
23 r ¼ 0.07, p ¼ 0.71 r ¼ 0.28, p ¼ 0.46
r ¼ 0.16, p ¼ 0.37 r ¼ 0.20, p ¼ 0.61
.358 r ¼ 0.12, p ¼ 0.51 r ¼ 0.21, p ¼ 0.59
, systolic blood pressure; DBP, diastolic blood pressure; PPSG,
A%B, insulin secretory capacity; HOMA%S, insulin sensitivity;
Figure 1: Relationship of serum visfatin levels with BMI of Control, IFG, IGT and IFG-IGT subjects.
Visfatin is associated with post-challenged plasma glucose levels in IGT subjects. 485level was found to be 2.6  1.2 ng/ml, which is similar with
the healthy Iranian population21 but less than a Spanish
population.11 A study on Chinese women22 also showed
much higher values of serum visfatin compared with the
Bangladeshi population. A number of articles have
reported increased levels of serum visfatin in type 2
diabetic and obese patients,21,23 but IFG and IGT subjects
have not been studied extensively regarding the serum
visfatin levels; however, it is essential to know whether the
increase in the circulating visfatin levels begin before the
onset of diabetes. Similar to type 2 diabetes mellitus, this
study showed increased levels of serum visfatin in the IFG
and IGT subjects compared with healthy Bangladeshi
control subjects, which suggests that increase in
hyperglycaemia and development of type 2 diabetes is
delayed through the hypersecretion of adipose tissue
derived visfatin. A recent experiment using streptozotocin-
induced diabetic rats also showed that visfatin has a signifi-
cant blood glucose lowering effect.24 Therefore, increased
serum visfatin levels may be a compensatory mechanism or
part of the pathophysiology of diabetes mellitus.
Contradictory results have also been outlined in a review
article.25 These discrepancies can be explained by the
different subject characteristics, the duration of T2DM andthe medication taken by the patients. Furthermore, there is
evidence that the release of visfatin by adipocytes is
dependent on the duration and magnitude of glucose
elevation.12 Visfatin is also associated with other diseases
including obesity, hypertension, dyslipidaemia, renal failure
and cardiovascular disease (CVD). The discrepancies in
clinical studies may be explained by the multifactorial
regulation of visfatin.
The blood pressure and BMI of the IFG, IGT and IFG-
IGT subjects were not different from the control subjects,
but both the systolic and diastolic pressure were found to be
significantly correlated with the serum visfatin levels in the
IGT subjects. Therefore, this finding suggests that inflam-
mationmay have a role in the development of hypertension in
type 2 diabetic patients, which is supported by a previous
study.26 In the present study, the BMI was found to be
significantly correlated with the visfatin levels in the IFG
and IGT subjects and marginally significant in the IFG-
IGT subjects, but it was not significant in the healthy con-
trols (Figure 1). These results are supported by a study carried
in Egypt,27 where patients with type 2 diabetes mellitus and
the BMI between the groups were not significantly
different, but the BMI in type 2 diabetic patients were
shown to be significantly associated with visfatin.
Table 4: Frequency distribution of NGT, IFG, IGT and IFG-IGT along with other clinical and biochemical parameters according to the
quartiles of the plasma visfatin concentrations among the study subjects.
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile
N (%) 27 (100) 27 (100) 27 (100) 27 (100)
M/F 18/9 11/16 11/16 10/17
aVisfatin, ng/ml 1.02 (0.4e1.79) 2.77 (1.79e3.37) 4.33 (3.44e6.10) 10.38 (6.25e18.20)
Glycaemic status
NGT, n (%) 18 (66.7) 9 (33.3) 7 (25.9) 6 (22.2)
IFG, n (%) 1 (3.7) 3 (11.1) 7 (25.9) 6 (22.2)
IGT, n (%) 7 (25.9) 12 (44.4) 9 (33.3) 11 (40.7)
IFG-IGT, n, (%) 1 (3.7) 3 (11.1) 4 (14.8) 4 (14.8)
c2 ¼ 17.86, p ¼ 0.037
Age, yrs 43  6 41  6 42  7 42  7
BMI, kg/m2 24.0  3.1 24.4  4.7 24.0  3.1 26.2  4.1*
BF, % 27.3  5.9 28.6  7.5 28.3  6.3 31.8  6.5**
SBP, mm-hg 114  16 111  13 109  12 117  12
DBP, mm-hg 74  10 73  8 74  9 79  8*
FG, mmol/l 5.3  0.5 5.5  0.7 5.6  0.7 5.6  0.7
PPG, mmol/l 6.8  1.6 7.8  2.1 7.7  2.2 8.2  1.9**
HOMA-IR 1.37  0.43 1.44  0.32 1.89  1.28* 1.57  0.65
TG, mg/dl 143  65 155  76 198  102* 157  71
M/F, male/female ratio.
NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMI, body mass index; BF%, body fat
percent; SBP, systolic blood pressure; DBP, diastolic blood pressure; FG, fasting glucose; PPSG, postprandial (2 h after a 75 g glucose
challenge) serum glucose; HOMA-IR, Insulin resistance using the HOMAmethod; TG, triglyceride in serum. *p < 0.05 compared with 1st
quartile and **p < 0.01 compared with 1st quartile in unpaired student’s t test.
a Visfatin expressed as median (range).
F. Kabir et al.486Although serum visfatin was raised in the hyperglycaemic
states, no significant correlation of fasting blood glucose with
visfatin was observed in this study, which contradicts the
findings of a previous study.28 The reason for this
discrepancy is unclear, but it may result from the study
different population because ethnic heterogeneity can affect
visfatin levels. The postprandial (2 h after a 75 g glucose
ingestion) serum glucose in the IGT subjects showed a
positive correlation with the fasting visfatin levels in this
study. The serum visfatin levels in the studied IFG, IGT
and IFG-IGT subjects did not exhibit any significant corre-
lation with insulin sensitivity, which is consistent with other
studies.9,29 Although animal experiments have shown
visfatin to display insulin-mimetic actions and increased
serum visfatin concentrations can respond to a compensa-
tory mechanism aimed at ameliorating the functional con-
sequences of insulin deficiency and promote insulin
sensitivity by its stimulatory effects on peroxisome pro-
liferatoreactivated receptor-g and adiponectin gene expres-
sion, both unresponsiveness to visfatin actions (as seen for
insulin and leptin) and a contribution of visfatin to b-cell
deterioration has been shown that circulating visfatin levels
are increased with progressive b-cell deterioration.11
Supporting these experimental findings, our study showed
that increasing concentrations of plasma visfatin levels
increased the frequency of IFG, IGT and IFG-IGT and
increased the trends of the 2 h post-challenge plasma glucose
and insulin resistance (HOMA-IR).
The major limitation of this study is the small number of
subjects recruited because of infrastructural constraints.
Additionally, measurements of mRNA expression levels in
the studied IFG, IGT and IFG-IGT subjects would enhance
this work.Conclusion
Our findings suggest that a) the serum visfatin levels
appear to be associated with IFG, IGT and IFG-IGT and b)
postprandial serum glucose and blood pressure are positively
associated with fasting serum visfatin levels in IGT subjects.
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